Phase 1 study evaluating the safety, distribution, metabolism, and radiation dosimetry of Ultratrace iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

Trial Profile

Phase 1 study evaluating the safety, distribution, metabolism, and radiation dosimetry of Ultratrace iobenguane I 131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2008

At a glance

  • Drugs Iobenguane (Primary)
  • Indications Neuroendocrine carcinoma
  • Focus Adverse reactions
  • Sponsors Molecular Insight Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2008 Positive preliminary results presented at the Annual Meeting of the American Society of Clinical Oncology 2008.
    • 22 Jan 2008 The expected completion date for this trial is now 1 Jan 2007.
    • 10 Dec 2007 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top